Literature DB >> 14567107

[Status and current strategies of HIV vaccine development].

J Wild1, R Wagner.   

Abstract

Despite intensive research efforts a vaccine against HIV has not yet been developed twenty years even after the onset of the HIV-epidemic. The problems in the development of an HIV-vaccine as well as former and current strategies to overcome these problems are presented here. The current status of human studies of different candidate vaccines is outlined.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14567107     DOI： 10.1007/s00108-003-0935-3

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN： 0020-9554            Impact factor:   0.834


  26 in total

Review 1.  Genetic diversity of HIV-1: the moving target.

Authors:  M Peeters; P M Sharp
Journal:  AIDS       Date:  2000       Impact factor: 4.177

2.  Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya.

Authors:  T Hanke; A J McMichael
Journal:  Nat Med       Date:  2000-09       Impact factor: 53.440

Review 3.  DNA vaccines.

Authors:  J J Donnelly; J B Ulmer; J W Shiver; M A Liu
Journal:  Annu Rev Immunol       Date:  1997       Impact factor: 28.527

4.  Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group.

Authors:  L Corey; M J McElrath; K Weinhold; T Matthews; D Stablein; B Graham; M Keefer; D Schwartz; G Gorse
Journal:  J Infect Dis       Date:  1998-02       Impact factor: 5.226

5.  Lymphoid organs function as major reservoirs for human immunodeficiency virus.

Authors:  G Pantaleo; C Graziosi; L Butini; P A Pizzo; S M Schnittman; D P Kotler; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-01       Impact factor: 11.205

6.  Assessing animal models of AIDS.

Authors:  J Stott; N Almond
Journal:  Nat Med       Date:  1995-04       Impact factor: 53.440

7.  Concerted action of multiple cis-acting sequences is required for Rev dependence of late human immunodeficiency virus type 1 gene expression.

Authors:  M Graf; A Bojak; L Deml; K Bieler; H Wolf; R Wagner
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

8.  Characterization of a virtually full-length human immunodeficiency virus type 1 genome of a prevalent intersubtype (C/B') recombinant strain in China.

Authors:  L Su; M Graf; Y Zhang; H von Briesen; H Xing; J Köstler; H Melzl; H Wolf; Y Shao; R Wagner
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

Review 9.  Safety and immunogenicity of recombinant human immunodeficiency virus-like particles in rodents and rhesus macaques.

Authors:  R Wagner; L Deml; F Notka; H Wolf; R Schirmbeck; J Reimann; V Teeuwsen; J Heeney
Journal:  Intervirology       Date:  1996       Impact factor: 1.763

10.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.

Authors:  D D Ho; A U Neumann; A S Perelson; W Chen; J M Leonard; M Markowitz
Journal:  Nature       Date:  1995-01-12       Impact factor: 49.962
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.